Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Interleukin-1 Receptor Type II (IL-1RII) is a member of the interleukin-1 receptor family and functions as a decoy receptor. It binds interleukin-1α (IL-1α), interleukin-1β (IL-1β), and interleukin 1 receptor antagonist (IL-1Ra), sequestering them away from the signaling-capable type I receptor complex, thereby preventing downstream inflammatory signal transduction and cell activation. Both membrane-bound and soluble forms exist, with the soluble form capable of binding free cytokines in circulation or tissue fluids. IL-1RII plays a crucial role in controlling excessive inflammation, particularly in macrophages, and its dysregulation is implicated in inflammatory diseases like arthritis.
Acts as a decoy receptor, binding IL-1α, IL-1β, and IL-1Ra to prevent their interaction with the signaling-competent IL-1RI, thus inhibiting downstream inflammatory signaling.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Interleukin 1 Receptor Type II (IL-1RII).